EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOTSG00005042522
Gene Symbol: PIK3CA
1 Cross references
191 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOTSG00005022499
Gene Symbol: PIK3CA
1 Cross references
146 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOTSG00005024533
Gene Symbol: PIK3CA
1 Cross references
150 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSOTSG00005005287
Gene Symbol: PIK3CB
3 Cross references
209 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSOTSG00005014468
Gene Symbol: PDE3A
1 Cross references
209 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSOTSG00005029434
Gene Symbol: PDE3A
1 Cross references
207 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSOTSG00005001674
Gene Symbol: PDE3B
1 Cross references
210 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSOTSG00005018252
Gene Symbol: PDE3B
1 Cross references
210 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSOTSG00005037991
Gene Symbol: PDE4A
1 Cross references
196 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSOTSG00005018718
Gene Symbol: PDE4A
3 Cross references
197 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSOTSG00005008821
Gene Symbol: PDE4B
1 Cross references
218 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSOTSG00005004523
Gene Symbol: PDE4B
1 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).